Physician profile
Robert J Ruffner
NPI 1871531632
$6,793.36
in general payments reported to CMS, 2019-2025
24 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $924 · 2021: $992 · 2022: $1,308 · 2023: $1,336 · 2024: $1,030 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,477.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,203.45 | 2019-2025 | |
| Amgen INC. | $993.38 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $796.75 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $631.07 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $595.52 | 2019-2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $492.35 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $369.73 | 2022-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $327.66 | 2019-2023 | |
| Pfizer INC. | $314.88 | 2019-2024 | |
| Amarin Pharma, INC. | $210.33 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $161.67 | 2019-2023 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $156.02 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $143.56 | 2022-2023 | Arcalyst |
| Boston Scientific Corporation | $58.54 | 2022-2023 | |
| Cvrx, INC. | $57.45 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $52.50 | 2022-2023 | Optimizer |
| Preventice Services, LLC | $45.59 | 2020-2021 | |
| Novo Nordisk INC | $35.52 | 2023 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.56 | 2023 | Lifevest |
| Cardiovascular Systems INC. | $34.49 | 2019-2020 | |
| Ge Healthcare | $28.69 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.55 | 2019 | |
| Esperion Therapeutics, INC. | $16.21 | 2021 | |
| Cardiva Medical, INC. | $15.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ruffner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.